LIFE - aTyr Pharma Inc. (LIFE) Q4 2023 Earnings Call Transcript
2024-03-14 23:37:06 ET
aTyr Pharma, Inc. (LIFE)
Q4 2023 Earnings Conference Call
March 14, 2024, 17:00 ET
Company Participants
Ashlee Dunston - Director, IR & Corporate Communications
Sanjay Shukla - President, CEO & Director
Jill Broadfoot - CFO
Conference Call Participants
Gregory Renza - RBC Capital Markets
Joe Pantginis - H.C. Wainwright & Co.
Yale Jen - Laidlaw & Company
Robert LeBoyer - Noble Capital Markets
Presentation
Operator
Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma fourth quarter and full year 2023 conference call. At this time, all participants are in a listen only mode. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes. It is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Director of Investor Relations and Public Affairs. Ms. Dunston, you may begin.
Ashlee Dunston
Thank you, and good afternoon, everyone. Thank you for joining us today to discuss aTyr's fourth quarter and full year 2023 operating results and corporate updates. We are joined today by Dr. Sanjay Shukla, our President and CEO, and Ms. Jill Broadfoot, our CFO.
On the call, Sanjay will provide an update on our corporate strategy, including our clinical program for Efzofitimod and research and discovery program. Jill will review our financial results and our current financial position before handing it back to Sanjay to open the call up for any questions.
Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.
Please see the forward-looking statement disclaimer in the company's press release issued this afternoon as well as the risk factors in the company's SEC filings and included in our most recent Annual Report on Form 10-K subsequently filed Quarterly Reports on Form 10-Q and in our other SEC filings.
Undue reliance should not be placed on forward-looking statements, which speak only as of the day they are made as facts and circumstances underlying these forward-looking statements may change. Except as required by law, aTyr Pharma disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances....
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript